Pengfei Xu1, Yue Xi2, Junjie Zhu1, Min Zhang1, Zigmund Luka3, Donna B Stolz4, Xinran Cai1, Yang Xie1, Meishu Xu1, Songrong Ren1, Zhiying Huang5, Da Yang1, John D York3, Xiaochao Ma1, Wen Xie6. 1. Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania. 2. Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China. 3. Department of Biochemistry, Vanderbilt University, Nashville, Tennessee. 4. Departments of Cell Biology, University of Pittsburgh, Pittsburgh, Pennsylvania. 5. School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China. 6. Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania. Electronic address: wex6@pitt.edu.
Abstract
BACKGROUND & AIMS: Sulfation is a conjugation reaction essential for numerous biochemical and cellular functions in mammals. The 3'-phosphoadenosine 5'-phosphosulfate (PAPS) synthase 2 (PAPSS2) is the key enzyme to generate PAPS, which is the universal sulfonate donor for all sulfation reactions. The goal of this study was to determine whether and how PAPSS2 plays a role in colitis and colonic carcinogenesis. METHODS: Tissue arrays of human colon cancer specimens, gene expression data, and clinical features of cancer patients were analyzed. Intestinal-specific Papss2 knockout mice (Papss2ΔIE) were created and subjected to dextran sodium sulfate-induced colitis and colonic carcinogenesis induced by a combined treatment of azoxymethane and dextran sodium sulfate or azoxymethane alone. RESULTS: The expression of PAPSS2 is decreased in the colon cancers of mice and humans. The lower expression of PAPSS2 in colon cancer patients is correlated with worse survival. Papss2ΔIE mice showed heightened sensitivity to colitis and colon cancer by damaging the intestinal mucosal barrier, increasing intestinal permeability and bacteria infiltration, and worsening the intestinal tumor microenvironment. Mechanistically, the Papss2ΔIE mice exhibited reduced intestinal sulfomucin content. Metabolomic analyses revealed the accumulation of bile acids, including the Farnesoid X receptor antagonist bile acid tauro-β-muricholic acid, and deficiency in the formation of bile acid sulfates in the colon of Papss2ΔIE mice. CONCLUSIONS: We have uncovered an important role of PAPSS2-mediated sulfation in colitis and colonic carcinogenesis. Intestinal sulfation may represent a potential diagnostic marker and PAPSS2 may serve as a potential therapeutic target for inflammatory bowel disease and colon cancer.
BACKGROUND & AIMS: Sulfation is a conjugation reaction essential for numerous biochemical and cellular functions in mammals. The 3'-phosphoadenosine 5'-phosphosulfate (PAPS) synthase 2 (PAPSS2) is the key enzyme to generate PAPS, which is the universal sulfonate donor for all sulfation reactions. The goal of this study was to determine whether and how PAPSS2 plays a role in colitis and colonic carcinogenesis. METHODS: Tissue arrays of human colon cancer specimens, gene expression data, and clinical features of cancer patients were analyzed. Intestinal-specific Papss2 knockout mice (Papss2ΔIE) were created and subjected to dextran sodium sulfate-induced colitis and colonic carcinogenesis induced by a combined treatment of azoxymethane and dextran sodium sulfate or azoxymethane alone. RESULTS: The expression of PAPSS2 is decreased in the colon cancers of mice and humans. The lower expression of PAPSS2 in colon cancer patients is correlated with worse survival. Papss2ΔIE mice showed heightened sensitivity to colitis and colon cancer by damaging the intestinal mucosal barrier, increasing intestinal permeability and bacteria infiltration, and worsening the intestinal tumor microenvironment. Mechanistically, the Papss2ΔIE mice exhibited reduced intestinal sulfomucin content. Metabolomic analyses revealed the accumulation of bile acids, including the Farnesoid X receptor antagonist bile acid tauro-β-muricholic acid, and deficiency in the formation of bile acid sulfates in the colon of Papss2ΔIE mice. CONCLUSIONS: We have uncovered an important role of PAPSS2-mediated sulfation in colitis and colonic carcinogenesis. Intestinal sulfation may represent a potential diagnostic marker and PAPSS2 may serve as a potential therapeutic target for inflammatory bowel disease and colon cancer.
Authors: Neil Murphy; Victor Moreno; David J Hughes; Ludmila Vodicka; Pavel Vodicka; Elom K Aglago; Marc J Gunter; Mazda Jenab Journal: Mol Aspects Med Date: 2019-06-28
Authors: Cees Noordam; Vivek Dhir; Joanne C McNelis; Florian Schlereth; Neil A Hanley; Nils Krone; Jan A Smeitink; Roel Smeets; Fred C G J Sweep; Hedi L Claahsen-van der Grinten; Wiebke Arlt Journal: N Engl J Med Date: 2009-05-28 Impact factor: 91.245
Authors: Guangfu Li; Dai Liu; Eric T Kimchi; Jussuf T Kaifi; Xiaoqiang Qi; Yariswamy Manjunath; Xinjian Liu; Tye Deering; Diego M Avella; Todd Fox; Don C Rockey; Todd D Schell; Mark Kester; Kevin F Staveley-O'Carroll Journal: Gastroenterology Date: 2018-01-31 Impact factor: 22.682
Authors: Malin E V Johansson; Jenny K Gustafsson; Jessica Holmén-Larsson; Karolina S Jabbar; Lijun Xia; Hua Xu; Fayez K Ghishan; Frederic A Carvalho; Andrew T Gewirtz; Henrik Sjövall; Gunnar C Hansson Journal: Gut Date: 2013-02-20 Impact factor: 23.059